Biohaven CEO says drug approval is 'monumental' for migraine patients
June 08, 2021 at 19:55 PM EDT
"This is going to change the paradigm in which migraine is treated," Biohaven Pharmaceutical CEO Vlad Coric said after Nurtec ODT received FDA approval.
